Why the study?
Does intravenous recombinant tissue plasminogen activator (t-PA) improve outcomes in patients with acute ischemic stroke?
Does intravenous recombinant tissue plasminogen activator (t-PA) improve outcomes in patients with acute ischemic stroke?
Answers are grounded in this paper and cite their sources.
This editorial discusses the role and limitations of thrombolytic therapy as a first-line treatment for acute ischemic stroke.
Thrombolysis — Not a Panacea for Ischemic StrokeThrombolysis with intravenous recombinant tissue plasminogen activator (t-PA) has quickly become part of the emergency care of patients with stroke. In December 1995, the report of a trial sponsored jointly by the National Institute of Neurological Disorders and Stroke (NINDS) and Genentech appeared in the Journal. 1 Shortly thereafter, the Food and Drug Administration (FDA) approved the use of t-PA for stroke, and committees of the American Heart Association2 and the American Academy of Neurology3 published guidelines endorsing its use. Appropriately, each organization emphasized the urgency of treatment. When it is effective, t-PA . . .
No takes yet. Share an insight, caveat, or question.
Caplan et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: